Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
2.040
-0.040 (-1.92%)
At close: Jul 31, 2025, 4:00 PM
2.060
+0.020 (0.98%)
After-hours: Jul 31, 2025, 7:23 PM EDT
Altus Power Employees
As of December 31, 2024, Gossamer Bio had 145 total employees, including 144 full-time and 1 part-time employees. The number of employees increased by 10 or 7.41% compared to the previous year.
Employees
145
Change (1Y)
10
Growth (1Y)
7.41%
Revenue / Employee
$859,241
Profits / Employee
-$353,366
Market Cap
463.70M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 145 | 10 | 7.41% |
| Dec 31, 2023 | 135 | -43 | -24.16% |
| Dec 31, 2022 | 178 | -7 | -3.78% |
| Dec 31, 2021 | 185 | -11 | -5.61% |
| Dec 31, 2020 | 196 | 25 | 14.62% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GOSS News
- 6 weeks ago - Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH - Business Wire
- 7 weeks ago - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 2 months ago - Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study - Business Wire
- 2 months ago - Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 - Business Wire
- 3 months ago - Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference - Business Wire
- 5 months ago - Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - Business Wire
- 5 months ago - Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD - Seeking Alpha